"We are very proud to be working with a world-renowned expert such as Dr. Chen and partnering with the NYU Medical Center in using PLX cells for the potential treatment of Diabetic Foot Ulcers," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "Our PLX-PAD cells have been shown to be safe and potentially effective and to improve the quality of life in patients with Peripheral Artery Disease (PAD), some of whom had suffered from ulcers. We are, therefore, excited about testing the PLX cells' effectiveness in treating DFU."
About the Helen L. and Martin S. Kimmel Wound Healing Center at NYUMC
The Helen L. and Martin S. Kimmel Wound Healing Center's mission is to eliminate limb loss in patients with lower extremity wounds and rapidly treat pressure ulcers before non-healing and complications ensue. The Kimmel program is unique in that it has members of eight departments available or involved in the care of each wound patient personified by the contributions from NYU faculty in the departments of Orthopedic Surgery, Medicine, Emergency Medicine, Plastic Surgery, Psychiatry, Dermatology, Anesthesia and Physiatry.
The Kimmel Center treats the elderly, disabled and those with diabetes who suffer with wounds in a personal and caring environment that involves patients and their families at every level of care. Under the Kimmel Centre's innovative, comprehensive, and compassionate care system, healing is not just an outcome, it's the expectation. This philosophy that every wound can heal is predicated on 29 years of study on the cellular basis of healing – from the clinic to the operating room to the research laboratories.About Pluristem Therapeutics Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. The PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20 million patients in the Peripheral Artery Disease (PAD) market.